UK markets closed
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • FTSE 250

    20,051.48
    -104.28 (-0.52%)
     
  • AIM

    920.38
    -2.34 (-0.25%)
     
  • GBP/EUR

    1.1851
    -0.0010 (-0.09%)
     
  • GBP/USD

    1.2071
    -0.0088 (-0.72%)
     
  • BTC-GBP

    19,137.80
    -136.13 (-0.71%)
     
  • CMC Crypto 200

    533.20
    -2.02 (-0.38%)
     
  • S&P 500

    4,145.19
    -6.75 (-0.16%)
     
  • DOW

    32,803.47
    +76.65 (+0.23%)
     
  • CRUDE OIL

    88.53
    -0.01 (-0.01%)
     
  • GOLD FUTURES

    1,792.40
    -14.50 (-0.80%)
     
  • NIKKEI 225

    28,175.87
    +243.67 (+0.87%)
     
  • HANG SENG

    20,201.94
    +27.90 (+0.14%)
     
  • DAX

    13,573.93
    -88.75 (-0.65%)
     
  • CAC 40

    6,472.35
    -41.04 (-0.63%)
     

Global Pharmaceutical Tracker, 2022

·1-min read
ReportLinker
ReportLinker

This research service offers comprehensive discussions about the key approvals, mergers and acquisitions, product licensing deals, and digital partnerships of the pharmaceutical industry in 2022. A renewed focus on operational excellence and digital transformation will push top-line pharmaceutical industry growth and drive strong partnerships with small and mid-size pharma and digital solution vendors.

New York, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pharmaceutical Tracker, 2022" - https://www.reportlinker.com/p06312015/?utm_source=GNW


The digital implosion is transforming the pharma business model to achieve digital maturity.Big pharma is moving toward technology vendor partnerships to accelerate digitization and de-risk investments in in-house capabilities, platforms, and solutions.

Diminishing R&D pipelines, stagnant productivity during the last 2 decades, and the disruption in clinical trials due to the pandemic have led to a surge in partnerships.Small and mid-sized companies will continue to attract big pharma and private equity (PE) firms.

New modalities and technologies will remain attractive for licensing deals, giving biotech licensor candidates a higher chance of negotiating contract terms and up-front payments.
Read the full report: https://www.reportlinker.com/p06312015/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting